Skip to main content
OpenTrials
Completed

NCT Number: NCT05866276

To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients

To determine the accuracy of SCreening for Occult REnal Disease (SCORED) questionnaire for CKD risk among Asian Patients

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Sensitivity and Specificity

    Time frame: 28 February 2024

    The primary objective is to evaluate the accuracy of SCORED tool in identifying individuals at risk for the development of CKD in the Asian population. The primary outcomes, sensitivity, and specificity will be summarised using percentage and 95% confidence intervals to be measured at Baseline up to 6months after enrollment

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Real-World Multicentre Prospective Study to Determine the Accuracy of the SCORED (SCreening for Occult REnal Disease) Questionnaire for SCreening REnal Risk Early Against Nephropathy in Adult Population in Asia

Acronym: SCREEN

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
May 19, 2023
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.